Search results
2 days ago · CHICAGO, June 27, 2024 — A workgroup convened by the Alzheimer’s Association has published revised criteria for the diagnosis and staging of Alzheimer’s disease that are based on the biology of the disease and reflect recent advancements in Alzheimer’s research, diagnostics and treatment. The 2024 update includes an updated biomarker ...
3 days ago · Alzheimer's disease (AD) is a neurodegenerative disease that usually starts slowly and progressively worsens, and is the cause of 60–70% of cases of dementia. The most common early symptom is difficulty in remembering recent events.
2 days ago · 1 BACKGROUND. In 2011, the National Institute on Aging and the Alzheimer's Association (NIA-AA) convened three workgroups that published separate recommendations for the diagnosis and evaluation of Alzheimer's disease (AD) in its preclinical, mild cognitive impairment (MCI), and dementia phases. 1-4 In 2012, an NIA-AA workgroup published a consensus document on the neuropathologic diagnosis of ...
2 days ago · Alzheimer's disease (AD) is a complex neurodegenerative disorder that affects up to 50 million patients 1, with projections indicating an increase to 131.5 million by the year 2050 2.It’s ...
5 days ago · In May 2023, drugmaker Lilly announced that its new Alzheimer’s drug, donanemab, slowed cognitive decline by 35 percent; in 2022, another drug, lecanemab, registered similarly promising results ...
4 days ago · Learn more here about the innovation ecosystem that Davos Alzheimer’s Collaborative is building to speed breakthroughs and end Alzheimer’s disease. Explore the transforming landscape of ...
5 days ago · Learn more here about the innovation ecosystem that Davos Alzheimer’s Collaborative is building to speed breakthroughs and end Alzheimer’s disease. Explore the transforming landscape of ...
